TIS tissue therapies limited

well, page-21

  1. 375 Posts.
    as noted above , possible revenues are projected for the first time, costs are unknown, a cap raising will be required, CE mark uncertainty , future EPS calulations need to account for coming dilution. Great product but long timeframes to meaningful profits even accounting for the market to anticipate and price in future earnings

    I'm still on the sidelines for the moment.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.